Tags

Type your tag names separated by a space and hit enter

Pharmacotherapy for the management of obesity.
Metabolism. 2015 Nov; 64(11):1376-85.M

Abstract

In the last 30 years, obesity has rapidly increased and obesity-related comorbidities have surged. Once considered to be a problem only in developed nations, obesity has become a global epidemic. Consequently, the costs associated with managing overweight and obesity worldwide are astronomical. The objective of this mini-review is to provide an overview of current options available for obesity management, with a focus on anti-obesity pharmacotherapies. The impact of weight loss on improving obesity-related comorbidities and risk factors has been well documented. Although established clinical guidelines suggest comprehensive lifestyle modification to induce weight loss, many patients do not respond to lifestyle interventions and may not qualify for bariatric surgery. For these patients, pharmacotherapy may serve as a therapeutic option. Several anti-obesity pharmacotherapies, such as phentermine, are indicated for short-term use and are not required to demonstrate clinically meaningful weight loss (i.e., ≥5%). For long-term weight management, the FDA has approved 5 agents so far-orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide. These drugs have shown efficacy in enabling patients to achieve clinically meaningful weight loss and improving cardiometabolic parameters. Healthcare practitioners can help alleviate the obesity epidemic by tailoring these pharmacotherapies based on individual needs, comorbidities, and associated drug safety concerns.

Authors+Show Affiliations

Pharmacy Practice, MCPHS University, 179 Longwood Avenue, Boston, MA 02115; VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130. Electronic address: Dhiren.patel1@mcphs.edu.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

26342499

Citation

Patel, Dhiren. "Pharmacotherapy for the Management of Obesity." Metabolism: Clinical and Experimental, vol. 64, no. 11, 2015, pp. 1376-85.
Patel D. Pharmacotherapy for the management of obesity. Metab Clin Exp. 2015;64(11):1376-85.
Patel, D. (2015). Pharmacotherapy for the management of obesity. Metabolism: Clinical and Experimental, 64(11), 1376-85. https://doi.org/10.1016/j.metabol.2015.08.001
Patel D. Pharmacotherapy for the Management of Obesity. Metab Clin Exp. 2015;64(11):1376-85. PubMed PMID: 26342499.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacotherapy for the management of obesity. A1 - Patel,Dhiren, Y1 - 2015/08/12/ PY - 2015/06/22/received PY - 2015/07/23/revised PY - 2015/08/07/accepted PY - 2015/9/7/entrez PY - 2015/9/8/pubmed PY - 2016/1/23/medline KW - Obesity KW - Obesity management KW - Pharmacotherapy KW - Weight loss SP - 1376 EP - 85 JF - Metabolism: clinical and experimental JO - Metab. Clin. Exp. VL - 64 IS - 11 N2 - In the last 30 years, obesity has rapidly increased and obesity-related comorbidities have surged. Once considered to be a problem only in developed nations, obesity has become a global epidemic. Consequently, the costs associated with managing overweight and obesity worldwide are astronomical. The objective of this mini-review is to provide an overview of current options available for obesity management, with a focus on anti-obesity pharmacotherapies. The impact of weight loss on improving obesity-related comorbidities and risk factors has been well documented. Although established clinical guidelines suggest comprehensive lifestyle modification to induce weight loss, many patients do not respond to lifestyle interventions and may not qualify for bariatric surgery. For these patients, pharmacotherapy may serve as a therapeutic option. Several anti-obesity pharmacotherapies, such as phentermine, are indicated for short-term use and are not required to demonstrate clinically meaningful weight loss (i.e., ≥5%). For long-term weight management, the FDA has approved 5 agents so far-orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide. These drugs have shown efficacy in enabling patients to achieve clinically meaningful weight loss and improving cardiometabolic parameters. Healthcare practitioners can help alleviate the obesity epidemic by tailoring these pharmacotherapies based on individual needs, comorbidities, and associated drug safety concerns. SN - 1532-8600 UR - https://www.unboundmedicine.com/medline/citation/26342499/Pharmacotherapy_for_the_management_of_obesity_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(15)00220-6 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.